

Supplemental table 8- Predictors of outcomes after biologics discontinuation in Crohn's Disease cohort

Predictors of poor outcomes	Time interval when significant	AUROC	Odds ratio (OR) and confidence intervals	Statistical significance
Secondary non-response	• < 6months	• 0.6213	• OR 4.29 95% CI (1.15 , 14.99)	• p=0.02
	• 6-12months	• 0.6628	• OR 5.93 95% CI (1.32 , 25.64)	• p= 0.02
	• >24 months	• 0.6575	• OR 6.53 95% CI (1.97 , 21.75)	• p=0.002
First biologic	• 12-24 months	• 0.6308	• OR 2.77 95% CI (1.22 , 7.03)	• p= 0.02
Predictors of good outcomes				
Male sex	• >24 months	• 0.6645	• OR 0.21 95% CI (0.05 , 0.69)	• p=0.02
Elective stop	• <6 months	• 0.6376	• OR 0.28 95% CI (0.06 , 0.98)	• p=0.07
	• 6-12 months	• 0.7475	None of the patients who had elective stop experienced an adverse outcome	• NA
Other predictors				
Sex	• < 6months	• 0.5558	• OR 0.63 95% CI (0.18 , 1.96)	• p= 0.44
	• 6-12months	• 0.5055	• OR 0.96 95% CI (0.23 , 3.82)	• p= 0.95
	• 12-24 months	• 0.5266	• OR 1.24 95% CI (0.42 , 3.64)	• p= 0.69
Race	• <6 months	• 0.5685	• OR 0.79 95% CI (0.52, 1.24)	• p= 0.28
	• 6-12months	• 0.5600	• OR 1.45 95% CI (0.8 , 2.87)	• p= 0.26
	• 12-24 months	• 0.5608	• OR 0.85 95% CI (0.57 , 1.32)	• p= 0.45
	• >24 months	• 0.5313	• OR 0.94 95% CI (0.63 , 1.46)	• p= 0.78
Rectal 5-ASA at baseline	• < 6months • 6-12months • 12-24 months • >24 months	• 0.5312 • 0.5297 • 0.5319 • 0.5323	None of the patients who were on this treatment experienced adverse outcomes	NA
Thiopurine at baseline	• < 6months	• 0.5833	• OR 2 95% CI (0.63 , 6.32)	• p= 0.23
	• 6-12months	• 0.6326	• OR 0.21 95% CI (0.01 , 1.19)	• p= 0.15
	• 12-24 months	• 0.5120	• OR 1.11 95% CI (0.35 , 3.26)	• p= 0.85
	• >24 months	• 0.5357		• p= 0.57

			<ul style="list-style-type: none"> OR 0.72 95% CI (0.21 , 2.13) 	
Steroid therapy at baseline	<ul style="list-style-type: none"> < 6months 6-12months 12-24 months >24 months 	<ul style="list-style-type: none"> 0.5126 0.5380 0.5811 0.5168 	<ul style="list-style-type: none"> OR 1.14 95% CI (0.29 , 3.74) OR 1.44 95% CI (0.29 , 5.89) OR 0.35 95% CI (0.05 , 1.38) OR 0.84 95% CI (0.22 , 2.63) 	<ul style="list-style-type: none"> p=0.84 p= 0.62 p= 0.19 p= 0.77
Endoscopic activity	<ul style="list-style-type: none"> < 6months 6-12months 12-24 months >24 months 	<ul style="list-style-type: none"> 0.5495 0.568 0.5086 0.5101 	<ul style="list-style-type: none"> OR 1.19 95% CI (0.76 , 2.29) OR 0.77 95% CI (0.5 , 1.26) OR 0.92 95% CI (0.63 , 1.44) OR 0.91 95% CI (0.63 , 1.4) 	<ul style="list-style-type: none"> p= 0.51 p= 0.25 p= 0.69 p= 0.64
First biologic	<ul style="list-style-type: none"> < 6months 6-12months >24 months 	<ul style="list-style-type: none"> 0.5204 0.6338 0.5247 	<ul style="list-style-type: none"> OR 1.35 95% CI (0.55 , 3.09) OR 2.33 95% CI (0.84 , 6.22) OR 1.01 95% CI (0.41 , 2.27) 	<ul style="list-style-type: none"> p= 0.49 p= 0.09 p= 0.99
Primary non-response	<ul style="list-style-type: none"> < 6months 6-12months 12-24 months >24 months 	<ul style="list-style-type: none"> 0.5149 0.5358 0.5266 0.5269 	<ul style="list-style-type: none"> OR 1.77 95% CI (0.09 , 13.16) OR 3.03 95% CI (0.15 , 23.83) <p>None of the patients who were had primary non-response experienced adverse outcomes</p>	<ul style="list-style-type: none"> p= 0.62 p= 0.35 NA NA
Secondary non-response	<ul style="list-style-type: none"> 12-24 months 	<ul style="list-style-type: none"> 0.5612 	<ul style="list-style-type: none"> OR 2.28 95% CI (0.57 , 7.84) 	<ul style="list-style-type: none"> p= 0.21
Side effects	<ul style="list-style-type: none"> < 6months 6-12months 12-24 months >24 months 	<ul style="list-style-type: none"> 0.5320 0.5693 0.5379 0.5405 	<ul style="list-style-type: none"> OR 0.49 95% CI (0.03 , 2.8) <p>None of the patients who had side effects experienced adverse outcomes</p> <ul style="list-style-type: none"> OR 0.42 95% CI (0.02 , 2.34) OR 0.38 95% CI (0.02 , 2.15) 	<ul style="list-style-type: none"> p= 0.51 NA p= 0.41 p= 0.37
Elective stop	<ul style="list-style-type: none"> 12-24 months >24 months 	<ul style="list-style-type: none"> 0.5831 0.5949 	<ul style="list-style-type: none"> OR 0.59 95% CI (0.18 , 1.68) OR 0.44 95% CI (0.13 , 1.3) 	<ul style="list-style-type: none"> p= 0.34 p= 0.16

Rectal 5-ASA following discontinuation	<ul style="list-style-type: none"> • < 6months • 6-12months • 12-24 months • >24 months 	<ul style="list-style-type: none"> • 0.5208 • 0.5198 • 0.5213 • 0.5215 	None of the patients who were on this treatment experienced adverse outcomes	NA
Thiopurine following discontinuation	<ul style="list-style-type: none"> • < 6months • 6-12months • 12-24 months • >24 months 	<ul style="list-style-type: none"> • 0.6295 • 0.6881 • 0.5559 • 0.5304 	<ul style="list-style-type: none"> • OR 2.93 95% CI (0.94 , 9.63) • None of the patients who were on this treatment experienced AO in this time frame • OR 0.59 95% CI (0.15 , 1.84) • OR 0.76 95% CI (0.23 , 2.24) 	<ul style="list-style-type: none"> • p= 0.07 • NA • p= 0.39 • p= 0.63